(MedPage Today) — CHICAGO — Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and hypercortisolism, a randomized placebo-controlled trial showed.
Among 136 patients, the least squares mean…
Source link : https://www.medpagetoday.com/meetingcoverage/ada/116204
Author :
Publish date : 2025-06-23 20:15:00
Copyright for syndicated content belongs to the linked Source.
